{"schema_version":"secwatch.filing_event.v1","accession":"0001437749-24-009476","form_type":"8-K","ticker":"ZVRA","cik":"0001434647","company_name":"ZEVRA THERAPEUTICS, INC.","filed_at":"2024-03-27T23:59:59+00:00","discovered_at":"2026-05-14T18:03:24.179754+00:00","generated_at":"2026-06-04T07:05:05.441587+00:00","sec_items":["7.01","8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Zevra reports positive Phase 2 top-line data for KP1077 in idiopathic hypersomnia","bullets":["KP1077 showed clinically meaningful improvement in excessive daytime sleepiness on ESS, maintained through open-label and double-blind phases.","Improvements also observed in IHSS, Sleep Inertia VAS, and Brain Fog severity scale at end of both open-label and double-blind periods.","Drug was well-tolerated at all doses (up to 320 mg/day); most common AEs were insomnia, headache, anxiety, nausea, decreased appetite.","Company plans to request end-of-Phase 2 meeting with FDA for guidance on Phase 3 trial design.","Study enrolled 66 patients; 50 continued into double-blind phase; not powered for statistical significance."],"urls":{"canonical":"https://secwatch.observer/filing/0001437749-24-009476","json":"https://secwatch.observer/filing/0001437749-24-009476.json","markdown":"https://secwatch.observer/filing/0001437749-24-009476.md","text":"https://secwatch.observer/filing/0001437749-24-009476.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1434647/000143774924009476/0001437749-24-009476-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1434647/000143774924009476/zvra20240326_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-04T07:05:05.441587+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}